- Home
- URGN vs PSNL Comparison
URGN vs PSNL Comparison
Compare URGN & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- PSNL
- Stock Information
- Founded
- URGN 2004
- PSNL 2011
- Country
- URGN United States
- PSNL United States
- Employees
- URGN N/A
- PSNL N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- URGN Health Care
- PSNL Health Care
- Exchange
- URGN Nasdaq
- PSNL Nasdaq
- Market Cap
- URGN 465.9M
- PSNL 460.7M
- IPO Year
- URGN 2017
- PSNL 2019
- Fundamental
- Price
- URGN $10.08
- PSNL $4.72
- Analyst Decision
- URGN Strong Buy
- PSNL Strong Buy
- Analyst Count
- URGN 6
- PSNL 4
- Target Price
- URGN $42.25
- PSNL $7.81
- AVG Volume (30 Days)
- URGN 308.1K
- PSNL 1.1M
- Earning Date
- URGN 03-13-2025
- PSNL 02-27-2025
- Dividend Yield
- URGN N/A
- PSNL N/A
- EPS Growth
- URGN N/A
- PSNL N/A
- EPS
- URGN N/A
- PSNL N/A
- Revenue
- URGN $89,363,000.00
- PSNL $87,489,000.00
- Revenue This Year
- URGN $12.17
- PSNL $16.00
- Revenue Next Year
- URGN $44.23
- PSNL $1.29
- P/E Ratio
- URGN N/A
- PSNL N/A
- Revenue Growth
- URGN 15.64
- PSNL 24.05
- 52 Week Low
- URGN $9.78
- PSNL $1.14
- 52 Week High
- URGN $20.70
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- URGN 40.55
- PSNL 43.46
- Support Level
- URGN $9.86
- PSNL $4.47
- Resistance Level
- URGN $11.87
- PSNL $6.43
- Average True Range (ATR)
- URGN 0.50
- PSNL 0.51
- MACD
- URGN -0.04
- PSNL 0.00
- Stochastic Oscillator
- URGN 10.95
- PSNL 12.50
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.